| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.074 | 0.2 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.073 | 0.2 |